GlobeNewswire by notified

BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 2023

Share

BBS-Bioactive Bone Substitutes, Company announcement, Insider information, 27 March 2023 at 7:20 p.m. EEST

BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 2023

The Notified Body has completed its second audit. The audit was carried out during 10-13 March 2023, the audit report was received on 20 March 2023, and today on 27 March 2023 the last meeting related to the audit was held with the authorities.

The second audit was related to the approval process of BBS-Bone Substitutes Plc’s quality system, which is part of the CE marking process for the company's first product (ARTEBONE® Paste -bone filler). During the second audit, the Notified Body inspected more closely detailed product documentation and the production processes.

According to the final audit report, certain additional measures are required from the company, and the company has committed to complete these by 1 September 2023. After this, the approval of the quality system is expected to be ready. CE marking is still expected to be obtained during 2023.

"Overall, we are satisfied with the results of the two audits, as we have now received information from the authorities about the non-conformities and are confident that we will be able to correct them. Also importantly, the supplementary measures required for the quality system approval will not slow down other ongoing related approval processes. The next important milestone will be to get a decision on the product classification, the processing of which has now been accelerated according to the authorities, even though they continue to have challenges with resourcing", says Ilkka Kangasniemi, CEO of BBS.

Previous disclosures related to the CE marking application:

  • 30 December 2023 – BBS-Bioactive Bone Substitutes Plc - Insider information: BBS updates estimate of the CE marking approval schedule of ARTEBONE® Paste
  • 18 November 2022 – BBS-Bioactive Bone Substitutes – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
  • 9 March 2022 – BBS Bioactive Bone Substitutes Plc has filed the CE-marking application of Artebone® bone void filler to the authorities

The CE marking process includes two main streams: approval of the quality system and product approval.  Obtaining product approval requires cooperation between the Notified Body and the Medicines Agency handling the matter.

For more information:

Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development, commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes, i.e. implants, are intended for the treatment of various bone damage, bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems. The company's head office is located in Oulu, and it employs 20 people.

BBS was founded in 2003, and the company has been listed on Nasdaq First North Growth Market Finland since February 2018.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Transactions in connection with share buyback programme6.6.2023 11:00:00 CEST | Press release

On 27 April 2022, Tryg A/S (“Tryg”) announced that a share buyback programme of DKK 5.0 billion had been initiated as a result of the sale of Codan Denmark. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 03 July 2023. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 30 May 2023 to 02 June 2023: Number of sharesAvg. purchase price, DKKTransaction value, DKK30 May 2023 40,000 159.74 6,389,60031 May 2023 50,000 158.86 7,943,00001 June 2023 50,000 157.98 7,899,00002 June 2023 70,000 157.74 11,041,800Accumulated for the period210,000-33,273,400Accumulated under the programme30,434,000-4,861,506,740 Detailed information

Kitron: Ny aksjekapital registrert6.6.2023 10:58:43 CEST | Pressemelding

(2023-06-06) Det vises til børsmelding fra Kitron ASA 1. juni 2023 vedrørende utstedelse av 526 081 nye aksjer under Selskapets aksjeinsentivprogram. Kapitalforhøyelsen i forbindelse med aksjeinsentivprogrammet har i dag blitt registrert i Foretaksregisteret. Registrert aksjekapital i Kitron ASA etter registreringen er NOK 19 821 713,40 fordelt på 198 217 134 aksjer hver pålydende NOK 0.10. Hver aksje gir én stemme på Selskapets generalforsamling. Kitron er et ledende skandinavisk foretak innen produksjon av elektronikk og relaterte tjenester for sektorene Konnektivitet, Elektrifisering, Industri, Medisinsk utstyr og Forsvar/Luftfart. Konsernet har virksomhet i Norge, Sverige, Danmark, Litauen, Tyskland, Polen, Tsjekkia, India, Kina og USA. Kitron har rundt 3 200 ansatte, og driftsinntektene var EUR 641 million i 2022. www.kitron.com (http://www.kitron.com) Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

Kitron: New share capital registered6.6.2023 10:58:43 CEST | Press release

(2023-06-06) Reference is made to the stock exchange announcement from Kitron ASA on 1 June 2023 regarding issuance of 526,081 new shares under the Company's share incentive program. The share capital increase in connection with the share incentive program has been registered in the Norwegian Register of Business Enterprises today. Registered share capital in Kitron ASA following the registration is NOK 19,821,713.40 divided on 198,217,134 shares, each with a par value of NOK 0.10. Each share gives one vote at the company's general meeting. Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group is located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China and the United States. Kitron has about 3 200 employees, and revenues were EUR 641 million in 2022. www.kitron.com (http://www.kitron.com) This information is subject to t

Prepayments (CK93) - Nykredit Realkredit A/S6.6.2023 10:28:00 CEST | Press release

To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 2 June 2023 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Nykredit Realkredit A/S Attachments Prepayments - Nykredit Realkredit A_S 06-06-2023eordindf

Ekstraordinære indfrielser (CK93) - Totalkredit A/S6.6.2023 10:28:00 CEST | pressemeddelelse

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 2. juni 2023 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Totalkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Totalkredit A_S 06-06-2023eordindftk